BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Leger D, Quera-Salva MA, Vecchierini MF, Ogrizek P, Perry CA, Dressman MA. Safety profile of tasimelteon, a melatonin MT1 and MT2 receptor agonist: pooled safety analyses from six clinical studies. Expert Opin Drug Saf 2015;14:1673-85. [PMID: 26393492 DOI: 10.1517/14740338.2015.1093112] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
Number Citing Articles
1 Săndulescu VA, Richter K. Mögliche Non-24-Schlaf-Wach-Rhythmusstörung?: Wiederherstellung der Arbeitsfähigkeit nach Behandlung mit Tasimelteon. Somnologie 2021;25:221-5. [DOI: 10.1007/s11818-021-00314-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Zhang R, Ni L, Di X, Ma B, Niu S, Rong Z, Liu C. Potential Role of Melatonin as an Adjuvant for Atherosclerotic Carotid Arterial Stenosis. Molecules 2021;26:811. [PMID: 33557283 DOI: 10.3390/molecules26040811] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Quera-Salva MA, Kilic-Huck U, Vecchierini MF; Members of the MEL consensus group of the SFRMS. Melatonin (MEL) and its use in circadian rhythm sleep-wake disorders: Recommendations of the French Medical and Research Sleep Society (SFRMS). Rev Neurol (Paris) 2021;177:235-44. [PMID: 33446328 DOI: 10.1016/j.neurol.2020.07.021] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Liampas I, Siokas V, Brotis A, Aloizou AM, Mentis AA, Vikelis M, Dardiotis E. Meta-analysis of melatonin levels in cluster headache-Review of clinical implications. Acta Neurol Scand 2020;142:356-67. [PMID: 32677039 DOI: 10.1111/ane.13317] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
5 Liampas I, Siokas V, Brotis A, Vikelis M, Dardiotis E. Endogenous Melatonin Levels and Therapeutic Use of Exogenous Melatonin in Migraine: Systematic Review and Meta‐Analysis. Headache: The Journal of Head and Face Pain 2020;60:1273-99. [DOI: 10.1111/head.13828] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 11.0] [Reference Citation Analysis]
6 Yadlapalli SSR, Karra VK, Kommineni V, Katari NK, Manabolu Surya SB. Bioanalytical technique for determination of tasimelteon in human plasma by LC-MS/MS and its application to pharmacokinetic study in humans. Biomed Chromatogr 2019;33:e4431. [PMID: 30412929 DOI: 10.1002/bmc.4431] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Posadzki PP, Bajpai R, Kyaw BM, Roberts NJ, Brzezinski A, Christopoulos GI, Divakar U, Bajpai S, Soljak M, Dunleavy G, Jarbrink K, Nang EEK, Soh CK, Car J. Melatonin and health: an umbrella review of health outcomes and biological mechanisms of action. BMC Med 2018;16:18. [PMID: 29397794 DOI: 10.1186/s12916-017-1000-8] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 7.3] [Reference Citation Analysis]
8 Ventimiglia G, Bellomi S, Barreca G, Giovannelli L, Masciocchi N. Synthesis, Characterization, and Crystal Chemistry of Tasimelteon, a Melatonin Agonist, in Its Anhydrous and Hemihydrate Forms. Journal of Pharmaceutical Sciences 2018;107:543-9. [DOI: 10.1016/j.xphs.2017.09.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
9 Quera Salva MA, Hartley S, Léger D, Dauvilliers YA. Non-24-Hour Sleep-Wake Rhythm Disorder in the Totally Blind: Diagnosis and Management. Front Neurol 2017;8:686. [PMID: 29326647 DOI: 10.3389/fneur.2017.00686] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 5.4] [Reference Citation Analysis]
10 Keating GM. Tasimelteon: A Review in Non-24-Hour Sleep-Wake Disorder in Totally Blind Individuals. CNS Drugs 2016;30:461-8. [DOI: 10.1007/s40263-016-0330-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]